PharmaEngine

PharmaEngine Deferred Tax Liabilities

The Deferred Tax Liabilities of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 4.96 M TWD.

Deferred Tax Liabilities

4.96 MTWD

Last updated:

Deferred Tax Liabilities of PharmaEngine is 2024 4.96 M TWD. Deferred Tax Liabilities of PharmaEngine was 2023 0.00 TWD. It decreases by % higher compared to the previous year.

The PharmaEngine Deferred Tax Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Deferred Tax Liabilities
Date
Deferred Tax Liabilities
Jan 1, 2016
10.45 M TWD
Jan 1, 2017
0.00 TWD
Jan 1, 2019
0.00 TWD
Jan 1, 2020
4,000.00 TWD
Jan 1, 2021
0.00 TWD
Jan 1, 2022
919,000.00 TWD
Jan 1, 2023
0.00 TWD
Jan 1, 2024
4.96 M TWD
The PharmaEngine Deferred Tax Liabilities history
YEARDeferred Tax LiabilitiesYoY
4.96 MTWD—
0.00TWD-100.00%
919,000.00TWD—
0.00TWD-100.00%
4,000.00TWD—
0.00TWD—
0.00TWD-100.00%
10.45 MTWD-20.09%
13.07 MTWD—
0.00TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Deferred Tax Liabilities of PharmaEngine is 4.96 M TWD in 2024.

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's PharmaEngine historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — PharmaEngine

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — PharmaEngine